You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Intravenous Ringer's Lactated Ringer's Solution from Any Water Source Without Electrical Power

    SBC: FOSMO MED, INC.            Topic: DHP172011

    Fosmo Med Lactate Ringer’s Solution (FMLRS) isasolutions bagthat is shipped around the world sans waterand can befilled with local water to createsterilelactated ringer’s solution within the bag withoutexternal power requirement. The primaryadvantage ofFMLRS is significant reduction of overall logistical cost sincethesolution is98% waterand accounts for themajority of theshippingcosts,which ca ...

    SBIR Phase I 2018 Department of DefenseDefense Health Agency
  2. Development of the JoRT Platform for Realistic Joint Reduction Training

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: DHA173002

    Joint reduction is a key skill and is a core competency for orthopedic surgeons deploying as part of a trauma team.Current training options are limited to classroom instruction on uninjured persons due to lack of a suitable training simulator. The first true reduction performed by medical providers is on actual patients. This method of instruction prevents the trainee from developing the comfort a ...

    SBIR Phase I 2018 Department of DefenseDefense Health Agency
  3. Handoff Training for Combat Casualty Care (HTC3) Framework

    SBC: Perceptronics Solutions, Inc.            Topic: DHA17B001

    This proposal is to develop a Handoff Training for Combat Casualty Care (HTC3) Framework.Training is the crux of the handoff problem today. Patient handoffs are a crucial part of casualty care, both in military and civilian environments; and today handoffs are being performed in less than optimal fashion, with ineffective communications accounting for 80% of the handoff errors. Our new HTC3 Framew ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  4. Combat Casualty Handoff Automated Trainer (CCHAT)

    SBC: SOAR TECHNOLOGY INC            Topic: DHA17B001

    Combat casualty handoffs are critical communication moments during which responsibility for the patient and important casualty information is transferred between providers. The nature of these handoffs requires specialized training, for which no standardized framework currently exists. The proposed effort aims to develop a capability, compatible with current DoD systems, that provides caregivers w ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  5. CCHAT Handoff Protocol

    SBC: SOAR TECHNOLOGY INC            Topic: DHA17B002

    Research has identified that handoffs are particularly important communication processes, during which communication error can lead to patient safety situations. Organizations have created standard practices and training materials to encourage teamwork communication for handoffs, however these do not necessarily capture the needs of military medicine of combat casualty care. Combat casualty handof ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  6. Griffon Test Suite

    SBC: SOAR TECHNOLOGY INC            Topic: DHA17C001

    In this proposal we support the development of a hypoxia test battery by designing and developing a domain general tool suite for processing, synchronizing, and evaluating data from cognitive, behavioral, and physiological measures.The proposed Griffon Tool Suite addresses many of the practical requirements demanded by a flexible test battery. The effort falls into three major thrusts.First, we pr ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus

    SBC: EVRYS BIO LLC            Topic: CBD18A002

    In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government